Annual revenues of Swedish biopharma company Sobi increased from around 6.5 billion Swedish kronor in 2017, up to the highest value of 26 billion Swedish kronor in 2024. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases. This statistic illustrates the annual revenue of Sobi from 2009 to 2024.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Sobi, & Nasdaq Nordic. (March 31, 2025). Revenue of Sobi from 2009 to 2024 (in million SEK) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 26, 2026, from /statistics/946914/annual-revenue-of-sobi/
Sobi, und Nasdaq Nordic. "Revenue of Sobi from 2009 to 2024 (in million SEK) ." Chart. March 31, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 26, 2026. /statistics/946914/annual-revenue-of-sobi/
Sobi, Nasdaq Nordic. (2025). Revenue of Sobi from 2009 to 2024 (in million SEK) . ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 26, 2026. /statistics/946914/annual-revenue-of-sobi/
Sobi, and Nasdaq Nordic. "Revenue of Sobi from 2009 to 2024 (in Million Sek) ." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 31 Mar 2025, /statistics/946914/annual-revenue-of-sobi/
Sobi & Nasdaq Nordic, Revenue of Sobi from 2009 to 2024 (in million SEK) ÌÇÐÄÆƽâ°æ, /statistics/946914/annual-revenue-of-sobi/ (last visited July 26, 2026)
Revenue of Sobi from 2009 to 2024 (in million SEK) [Graph], Sobi, & Nasdaq Nordic, March 31, 2025. [Online]. Available: /statistics/946914/annual-revenue-of-sobi/
